Phase I study of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2016
At a glance
- Drugs Ixabepilone (Primary)
- Indications Cancer
- Focus Adverse reactions
- 09 Oct 2008 Actual patient number changed from 71 to 59, as reported by Clinicaltrials.gov.
- 05 Aug 2008 Actual patient number added from ClinicalTrials.gov.
- 05 Aug 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.